ARS PHARMACEUTICALS INC (SPRY)
Health Care · Specialty biopharmaceuticals / emergency allergy treatment · NASDAQ
Biopharmaceutical company commercializing neffy, the only FDA-approved needle-free intranasal epinephrine for emergency anaphylaxis treatment.
What ARS PHARMACEUTICALS INC does
ARS Pharmaceuticals is a biopharmaceutical company commercializing neffy (EURneffy/优敏速), a needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions and anaphylaxis. Neffy is the company's only approved product, currently available in the United States, EU, United Kingdom, Japan, Australia, China, and Canada. The company is focusing significant resources on commercializing neffy through collaboration partners while developing additional product candidates using intranasal epinephrine technology.
Themes: ["Anaphylaxis emergency treatment","Needle-free drug delivery","Intranasal epinephrine technology","Allergic reaction management"]
Fundamentals
- Price$7.88 as of 2026-07-09 close
- Market cap$783M as of 2026-07-10
- 1-year return-52.2% as of 2026-07-09 close
- Net margin-200.0% as of 2026-07-10
- Gross margin+74.1% as of 2026-07-10
- ROE-153.6% as of 2026-07-10
- Debt / equity1.57 as of 2026-07-10
- Revenue growth (YoY)+1.9% as of 2026-07-10
- Revenue CAGR (3y)+300.1% SEC XBRL
- Beta1.00 as of 2026-07-10
Key risks (from latest filing)
["Neffy is the company's only approved product; unsuccessful commercialization would materially adversely affect the business and stock price","Company has no prior experience commercializing any product, with significant uncertainty regarding physician and patient adoption of neffy versus traditional epinephrine auto-injectors","Dependence on collaboration partners (ALK Co-Promotion Agreement) for sales force execution; inability to recruit/retain adequate sales personnel or access physicians could hinder market penetration"]
Competitors & peers
- Mylan (traditional epinephrine auto-injector market)
- Kaléo (emergency epinephrine solutions)
- Adamis Pharmaceuticals (epinephrine products)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.